MP08-03 PROGRESSION-FREE SURVIVAL AS SURROGATE ENDPOINT IN HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER STUDIES: RESULTS FROM A MACHINE LEARNING-BASED ANALYSIS OF A LARGE MULTI-INSTITUTIONAL DATABASE
MP08-03 PROGRESSION-FREE SURVIVAL AS SURROGATE ENDPOINT IN HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER STUDIES: RESULTS FROM A MACHINE LEARNING-BASED ANALYSIS OF A LARGE MULTI-INSTITUTIONAL DATABASE
M. Marchioni,A. Porreca,36 Authors,M. Ferro
TLDR
PFS represents a good surrogate endpoint of OS considering its strong independent predictor status and the high accuracy, and future studies evaluating the HR-NMIBC treatments can safely rely on PFS as surrogate of OS.
Abstract
(cid:5) 62.5 months (HR: 0.2, p < 0.001). CONCLUSIONS: Our results suggest that PFS represent a good surrogate endpoint of OS considering its strong independent predictor status and the high accuracy. Future studies evaluating the ef fi cacy of HR-NMIBC treatments can safely rely on PFS as surrogate of OS.